In reaction to strong earnings/guidance:

AVCT +17.6%, ALTR +9.4%, DTLK +8.7%, GKK +7.1%, KNL +6.7%, LEG +6.6%, CCK +6.3%, CAVM +5.7%, ATR +4.0%, FHN +3.3%, TXT +2.9%, FCS +2.6%, IBM +2.4% (also upgraded to Buy and $150 tgt at Canaccord), CHKP +2.3%, TCBI +1.6%, CY +1.6%... M&A news: IDGR +2.6% (to be acquired by WCC for $11.75/share)... Other news: ABPI +35.8% (says independent DMC recommends presenting data on BiovaxID to FDA and worldwide regulatory agencies in order to seek marketing approvals for Follicular Non-Hodgkin's Lymphoma), AVAN +28.9% (Pfizer and AVANT enter into licensing and development agreement for novel therapeutic vaccine candidate for brain cancer), SPPI +7.6% (presents data on lucanthone; preclinical data demonstrates potential applications in lung cancer therapy), ICO +5.6% (still checking), TASR +3.8% (receives follow-on overseas order for TASER cartridges), ISIS +2.8% (GSK and Regulus Therapetuics, JV between ALNY and ISIS, form strategic alliance to develop MicroRNA targeted therapeutics to treat inflammatory diseases)... Analyst upgrades: OMTR +5.3% (upgraded to Buy at Citigroup), CPHD +1.4% (upgraded to Buy at UBS), HK +1.4% (initiated with Buy at UBS).